National Comprehensive Cancer Network



About NCCN

Smoking Cessation Panel - Disclosures as of 9/20/2014

View NCCN Management Team Disclosures | View NCCN Guidelines Staff Disclosures | View NCCN ORP Staff Disclosures

Panel Member Clinical Research Support/Data Safety Monitoring Board Advisory Boards, Speakers Bureau, Expert Witness, or Consultant Patent, Equity, or Royalty Other Date Completed

Douglas Arenberg, MD, MS

Mauna Kea Technologies

None

None

None

8/27/2014

Laura Bierut, MD

None

Imedex;
National Institute on Drug Abuse Advisory Coucil on Drug Abuse

Dr. Bierut is listed as an inventor on Issued US Patent 8,080,371,Markers

None

8/8/2014

Jennifer Burns

None

None

None

None

7/10/2014

Julie Bylund Luckart, APRN, AOCN, FNP

None

Genentech, Inc.;
Pfizer Inc.

None

None

9/5/2014

Paul Cinciripini, PhD

Pfizer Inc.

None

None

None

8/28/2014

Bradley Collins, PhD

National Cancer Institute

None

None

None

9/18/2014

Sean David, MD, SM, DPhil

BaseHealth, Inc.

BaseHealth, Inc.

None

None

9/4/2014

James Davis, MD

None

None

None

None

8/22/2014

Kristina M. Gregory, RN, MSN, OCN

None

None

None

None

9/16/2014

Brian Hitsman, PhD

None

None

None

None

9/19/2014

Andrew Hyland, PhD

;
National Cancer Institute;
National Institute on Drug Abuse

None

None

None

6/10/2014

Margaret Lang, MSN

None

None

None

None

9/7/2014

Scott Leischow, PhD

National Cancer Institute;
e-Nicotine Technology;
NJOY;
Tobacco Regulatory Sciences group;
University of Minnesota

University of Chicago Cancer Center

None

Institute of Medicine;
Tobacco Regulatry Sciences Group

9/8/2014

Joan S. McClure, MS

None

None

None

None

6/20/2014

Elyse R. Park, PhD

None

None

None

None

8/27/2014

W. Thomas Purcell, MD, MBA

None

None

None

None

8/11/2014

Stephen Rennard, MD

GlaxoSmithKline;
Otsuka;
Pearl;
Prostaglandin Inhibition in Emphysema grant

AstraZeneca Pharmaceuticals LP;
AstraZeneca Pharmaceuticals LP;
Boehringer Ingelheim GmbH;
Boehringer Ingelheim GmbH;
Daiichi- Sankyo Co.;
GlaxoSmithKline;
GlaxoSmithKline;
Johnson & Johnson;
Johnson & Johnson;
MedImmune Inc.;
Merck & Co., Inc.;
Novartis Pharmaceuticals Corporation;
Novartis Pharmaceuticals Corporation;
ABIM;
Able Associates;
Almirall;
Chiesi;
Chiesi;
CIPLA;
Cipla;
CME Incite;
Corey Path;
CSA;
CSA Medical;
CSL Behring;
CTS Carmel;
Decision Resources;
First Word;
Forestweb program;
Frankel Group;
Gerson Lehman;
Gilead;
Guidepoint Global;
LEK Consulting;
Medical Knowledge;
Nycomed;
Pearl;
Pro Ed Comm;
Pulmatrix;
Quadrant;
Regeneron;
Regeron;
Saatchi and Saatchi;
Schlesinger Associates;
Synapse;
Takeda;
Pfizer Inc.;
Takeda Pharmaceuticals North America, Inc.

None

None

9/17/2014

Jillian L. Scavone, PhD

None

None

None

None

3/4/2014

Peter G. Shields, MD

None

National Cancer Institute;
Various law firms for chemical exposure cases

None

None

8/22/2014

Andrea Silber, MD

None

Novartis Pharmaceuticals Corporation;
Publicis

None

None

9/6/2014

Sharon Spencer, MD

None

None

None

None

6/13/2014

Tawee Tanvetyanon, MD

None

None

None

None

9/3/2014

Brian Tiep, MD

Chad Therapeutics;
Nonin Medical

Chad Therapeutics;
Nonin Medical

None

None

8/6/2014

Hilary Tindle, MD, MPH

None

None

None

None

9/8/2014

Reginald Tucker-Seeley, MA, ScM, ScD

None

None

None

None

8/21/2014

James Urbanic, MD

       

Pending

Benny Weksler, MD, MBA, FACS

       

Pending

C. Will Wikle, NP, RN

None

None

None

None

8/28/2014

Douglas E. Wood, MD

Spiration

Lung Cancer Alliance;
Spiration, Inc.

None

None

9/16/2014